SCHEMBL924899

SCHEMBL924899

Cc1csc(Nc2ncccn2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.58
KMT2A Q03164 9/20 0.58
GAA P10253 7/20 0.58
TRPV4 Q9HBA0 1/20 0.56
SMN1; SMN2 Q16637 9/20 0.56
MAPT P10636 9/20 0.56
NPC1 O15118 8/20 0.56
MEN1 O00255 8/20 0.56
ALDH1A1 P00352 7/20 0.55
POLB P06746 3/20 0.55
HTT P42858 3/20 0.55
THRB P10828 2/20 0.55
MCL1 Q07820 2/20 0.55
APEX1 P27695 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
ATM Q13315 1/20 0.54
MAPK1 P28482 1/20 0.53
SPHK2 Q9NRA0 1/20 0.53
SPHK1 Q9NYA1 1/20 0.53
TYR P14679 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762492 0.80 SPHK2 (0.46) RAB9AKMT2AGAATRPV4SMN1; SMN2
SCHEMBL12215995 0.79 RAB9A (0.65) RAB9AKMT2AGAATRPV4SMN1; SMN2
SCHEMBL9072510 0.78 RAB9A (0.68) RAB9AKMT2AGAASMN1; SMN2MAPT
SCHEMBL191576 0.75 GCK (0.59) RAB9AKMT2AGAASMN1; SMN2MAPT
SCHEMBL1328439 0.75 GCK (0.60) RAB9AKMT2AGAASMN1; SMN2MAPT
SCHEMBL1328161 0.75 GCK (0.60) RAB9AKMT2AGAASMN1; SMN2MAPT
SCHEMBL4548018 0.73 GAA (1.00) RAB9AKMT2AGAATRPV4SMN1; SMN2
SCHEMBL15993435 0.73 KMT2A (0.67) RAB9AKMT2AGAATRPV4SMN1; SMN2
SCHEMBL3377675 0.73 GCK (0.63) RAB9AKMT2AGAASMN1; SMN2MAPT
SCHEMBL18281285 0.72 MEN1 (1.00) RAB9AKMT2AGAATRPV4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868188-B2 5-heteroaryl thiazoles and their use as PI3K inhibitors ASTRAZENECA AB (SE) 2011-01-11 US disclosed
EP-1841763-B1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS ASTRAZENECA AB (SE) 2010-06-30 EP disclosed
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ASTRAZENECA AB (SE) 2008-06-05 US disclosed
EP-1841763-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS AstraZeneca AB (SE) 2007-10-10 EP disclosed
WO-2006051270-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS ASTRAZENECA AB (SE) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors MTOR, PIK3R5, PIK3CA RAB9A 675/4885KMT2A 2805/4885GAA 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.